AgomAb Therapeutics NV American Depositary Shares

Market Cap

$608M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$12.63-$3.37 (-21.06%)

Jul 15, 2026

52W High $17.8252W Low $9.61

Company Details

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), a...

Leadership

Tim Knotnerus MSc, Ph.D.

CEO & Executive Director

Paolo Michieli Ph.D.Founder

Founder, Senior Advisor & Member of Scientific Advisory Board

Pierre Kemula B.Sc.

Chief Financial Officer

Sofie Van Gijsel

Vice President of Investor Relations

Ellen Lefever

General Counsel

Philippe Wiesel M.D.

Chief Medical Officer

Paul Van Der Horst Ph.D.

Chief Business Officer

Andrea Sáez Borderías Ph.D.

Chief Development Officer

IPO Date

Feb 6, 2026

Website

www.agomab.com

Key Metrics TTM (EUR)

Revenue

- YoY

Net Income

-€12M

EPS (Diluted)

Free Cash Flow

-€13M

Revenue / Share

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Revenue & Profitability (EUR)

Operating Cash Flow (EUR)

CapEx Spend (EUR)

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation (EUR)

OpEx Breakdown (EUR)

War Chest (EUR)

Shares Outstanding